Ashish Kamat hosts Sam Chang to discuss the SunRISe-3 trial. Dr. Chang presents the ongoing trial investigating the efficacy of TAR-200, either alone or combined with cetrelimab, against BCG in treating patients with BCG-naive bladder cancer. TAR-200, a targeted release system using gemcitabine, is tested for its potential benefits over traditional treatments due to its unique delivery system aimed at reducing treatment frequency and side effects. With most trial participants already enrolled, Dr. Chang anticipates significant insights by the second quarter of 2025. This trial could shift treatment paradigms, offering a promising alternative to BCG, particularly given its current shortages and treatment burdens.

Biographies:

Sam S. Chang, MD, MBA, Patricia and Rodes Hart Endowed Chair of Urologic Surgery Professor Department of Urology at Vanderbilt University Medical Center

Ashish Kamat, MD, MBBS, is a Professor of Urology and Cancer Research and Wayne B. Duddleston Professor of Cancer Research at MD Anderson Cancer Center in Houston, Texas. Dr. Kamat serves as President of International Bladder Cancer Group, (IBCG), and Co-President of International Bladder Cancer Network.